Summary

Thyrocare Technologies Limited announced robust financial results for Q4FY26 and the full fiscal year 2026. For Q4FY26, consolidated revenue grew 20% year-on-year to ₹223.95 crore, driven by strong performance in the Pathology segment. Profit After Tax (PAT) showed exceptional growth, surging 128% year-on-year to ₹48.70 crore, while EBITDA increased by 31% to ₹75.09 crore. For the entire fiscal year 2026, the company reported a consolidated revenue of ₹829.04 crore, up 21% YoY, with PAT rising 81% to ₹162.85 crore and EBITDA growing 38% to ₹262.04 crore. Management highlighted a strong focus on operational efficiency, network expansion, and the strategic strengthening of its specialty diagnostics portfolio, including entry into genomics, as key drivers for this performance.

Key Highlights

1. 1

   Thyrocare Technologies Limited reported consolidated revenue of ₹223.95 Cr for Q4FY26, registering a strong 20% year-on-year growth, primarily driven by a 21% increase in the Pathology segment.

2. 2

   For the fourth quarter of fiscal year 2026, consolidated EBITDA rose by 31% year-on-year to ₹75.09 crore, while Profit After Tax (PAT) surged by an impressive 128% year-on-year to ₹48.70 crore.

3. 3

   The company processed 59.0 million tests in Q4FY26, marking a significant 29% year-on-year growth and reinforcing its volume leadership in the diagnostics industry.

4. 4

   For the full fiscal year 2026, consolidated revenue grew by 21% year-on-year to ₹829.04 crore, with pathology franchise revenue up 18% YoY and partnership revenue up 32% YoY.

5. 5

   Full-year FY26 consolidated EBITDA increased by 38% year-on-year to ₹262.04 crore, and Profit After Tax grew by 81% year-on-year to ₹162.85 crore.

6. 6

   Thyrocare strengthened its specialty portfolio by expanding advanced allergy testing and foraying into genomics with the launch of Non-invasive Pre-Natal Testing (NIPT).

7. 7

   The company achieved Six Sigma quality standards by reducing complaints per million tests to 3.1, a 34% year-on-year reduction, with an Average Turnaround Time (ATAT) of 3.43 hours.